Skip to main content
Premium Trial:

Request an Annual Quote

Rennova's Medytox Diagnostics Partners With Genomas to Launch PGx Testing

NEW YORK (GenomeWeb) – Rennova Health subsidiary Medytox Diagnostics has partnered with Genomas to launch a series of pharmacogenetics tests to determine a patient's capacity to metabolize certain drugs and potentially tailor treatments to an individual's specific genetic makeup.

The tests they will be performed via a US Food and Drug Administration-approved in vitro diagnostic (IVD) genotyping kit.

Genomas, a Hartford, Connecticut-based personalized medicine company, has developed PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease, and diabetes.

The new testing is designed to yield superior patient outcomes and help reduce healthcare system costs by properly diagnosing and treating each and every patient from the inception of their illness, West Palm Beach, Florida-based Rennova Health said in a statement.

"Securing the ability to provide this modern DNA analysis and interpretation further demonstrates our commitment to expand the diagnostic solutions we offer to medical providers," Rennova Health CEO Seamus Lagan said in a statement.